GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Adagio Medical Holdings Inc (NAS:ADGM) » Definitions » Treasury Stock

ADGM (Adagio Medical Holdings) Treasury Stock : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Adagio Medical Holdings Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Adagio Medical Holdings's treasury stock for the quarter that ended in Sep. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Adagio Medical Holdings Treasury Stock Historical Data

The historical data trend for Adagio Medical Holdings's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagio Medical Holdings Treasury Stock Chart

Adagio Medical Holdings Annual Data
Trend Dec21 Dec22 Dec23
Treasury Stock
- - -

Adagio Medical Holdings Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24
Treasury Stock Get a 7-Day Free Trial Premium Member Only - - - - -

Adagio Medical Holdings Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Adagio Medical Holdings Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
26051 Merit Circle, Suite 102, Laguna Hills, CA, USA, 92653
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.